natgillin/translations-raw huggingface dataset:
decrease in blood pressure, breathlessness, loss of consciousness, cardiac/cardio-respiratory arrest or more severe reaction with difficulties in breathing and dizziness)
znižanjem krvnega tlaka, oteženim dihanjem, izgubo zavesti, srčnim/kardio-respiratornim zastojem ali hujšo reakcijo s težavami z dihanjem in omotico).
Other medicines and SonoVue
Druga zdravila in zdravilo SonoVue
What SonoVue is and what it is used for
Kaj je zdravilo SonoVue in za kaj ga uporabljamo
Final study report to be submitted by 2Q 2020
Oddaja Končnega poročila Drugo četrtletje 2020
No clinical data are available.
Plodnost Klinični podatki niso na razpolago.
Sulphur hexafluoride is an inert, innocuous gas, poorly soluble in aqueous solutions.
Žveplov heksafluorid je inerten, neškodljiv plin, slabo topen v vodnih raztopinah.
It is recommended to keep the patient under close medical supervision during and for at least 30 minutes following the administration of SonoVue.
Priporočljivo je, da je bolnik pod strogim zdravniškim nadzorom med in še vsaj 30 minut po prejetju zdravila SonoVue.
• In paediatric patients the recommended dose of SonoVue is 1mL.
• pri pediatričnih bolnikih je priporočen odmerek zdravila SonoVue 1 ml. Način uporabe
A single-dose study and a repeat-dose study, both followed by a treatment-free period, were performed in female rats with local toxicity evaluated through macroscopic and histopathological examination of both kidneys, ureters, the urinary bladder and urethra.
Študiji z enim odmerkom in študiji z večkratnimi odmerki, katerima je sledilo obdobje brez zdravljenja, sta bili izvedeni na podganjih samicah, pri katerih je bila lokalna toksičnost ocenjena na podlagi makroskopskih in histopatoloških preiskav obeh ledvic, sečevodov, sečnega mehurja in uretre.
- The active substance is sulphur hexafluoride in the form of microbubbles.
- Zdravilna učinkovina je žveplov heksafluorid v obliki mikromehurčkov.
For ultrasound scan of heart or your blood vessels and/or tissues of the liver and breast in adults:the dose to be administered into a vein will be calculated for you depending on which part of your body is being examined.
Ultrazvok srca ali krvnih žil in/ali tkiva jeter in dojk pri odraslih: odmerek, ki se ga daje v veno bo za vas izračunan na podlagi dela telesa, ki bo pregledan.
Reconstitution instructions:
Navodilo za rekonstitucijo:
SonoVue is for diagnostic use only.
Zdravilo SonoVue je samo za diagnostične namene.
Shake vigorously for 20 seconds to mix all the contents in the vial to obtain a white milky homogeneous liquid.
Močno stresajte 20 sekund, da se vsebina viale premeša in nastane mlečna, homogena tekočina.
• B-mode imaging of cardiac chambers, at rest or with stress: 2 mL.
• preiskava srčnih prekatov način-B, pri mirovanju ali pri obremenitvi: 2 ml,
Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.
Preobčutljivost na zdravilno učinkovino ali katerokoli pomožno snov, navedeno v poglavju 6.1.
After reconstitution, SonoVue is a homogeneous white milky dispersion.
Po rekonstituciji je zdravilo SonoVue homogena belomlečna disperzija.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 25 mg powder
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 25 mg praška
The undesirable effects reported with SonoVue after intravenous administration were, in general, non-serious, transient and resolved spontaneously without residual effects.
Neželeni učinki, poročani pri zdravilu SonoVue po intravenski aplikaciji, so bili na splošno neresni, prehodni in so izginili spontano brez učinkov.
The sulphur hexafluoride dissolves in the blood and is subsequently exhaled.
Žveplov heksafluorid se raztopi v krvi in se pozneje izloči v izdihanem zraku.
SonoVue does not affect the ability to drive and use machines.
Zdravilo SonoVue ne vpliva na sposobnost vožnje in upravljanja s stroji.
The safety and efficacy of SonoVue in patients under 18 years of age has not been established for intravenous administration and use in echocardiography and vascular Doppler imaging.
Varnost in učinkovitost zdravila SonoVue pri bolnikih mlajših od 18 let ni bila ugotovljena za intravensko uporabo in uporabo pri ehokardiografskem in vaskularnem dopplerskem slikanju.
SonoVue must not be used in combination with dobutamine in patients with conditions suggesting cardiovascular instability where dobutamine is contraindicated.
Zdravilo SonoVue se ne sme uporabljati v kombinaciji z dobutaminom pri bolnikih, ki kažejo na kardiovaskularno nestabilnost, kjer je dobutamin kontraindiciran.
At the proposed clinical doses for intravenous administration, SonoVue has been shown to provide marked increase in signal intensity of more than 2 minutes for B-mode imaging in echocardiography and of 3 to 8 minutes for Doppler imaging of the macrovasculature and microvasculature.
Pri predlaganih kliničnih odmerkih za intravensko uporabo izkazuje zdravilo SonoVue znaten porast jakosti signala za več kot 2 minuti pri ehokardiografiji z B-načinom slikanja in za 3 do 8 minut pri dopplerskem slikanju velikih žil in mikrovaskularizacije.
Not known (frequency cannot be estimated from the available data): - Faintness - In some of the cases of allergic reactions, in patients with cardiac blood vessel disease, lack of oxygen supply of the heart or cardiac arrest were reported - Vomiting
Neznana (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov): - omedlevica, - pri nekaterih primerih alergijskih reakcij, pri bolnikih s koronarno srčno boleznijo so poročali tudi o slabi oskrbi srca s kisikom ali srčnemu infarktu, - bruhanje.
The product is for a single examination only.
Zdravilo je namenjeno za uporabo pri samo enem pregledu.
The vial is then shaken vigorously for twenty seconds after which the desired volume of the dispersion can be drawn into a syringe as follows:
Nato vialo močno stresajte 20 sekund, nato pa z injekcijsko brizgo odvzemite želeni volumen disperzije po sledečem postopku:
In particular, please tell your doctor if you are taking beta-blockers (medicines for heart disease and hypertension or for glaucoma in eye drops).
Zlasti obvestite zdravnika, če jemljete zaviralce adrenergičnih receptorjev beta (zdravila za bolezni srca in hipertenzijo ali za glavkom v kapljicah za oči).
After introduction of a sterile 6F-8F urinary catheter into the bladder under sterile conditions, the bladder is emptied of urine and then filled with saline (normal sterile 0.9% sodium chloride solution) to approximately one third or half of its predicted total volume [(age in years + 2) x 30] mL.
Po vstavitvi sterilnega 6F-8F urinskega katetra v mehur pod sterilnimi pogoji, se mehur izprazni in nato napolni s fiziološko raztopino (normalno sterilno 0,9 % raztopino natrijevega klorida) do približno ene tretjine ali polovice predvidenega celotnega volumna [(starost v letih + 2) x 30] ml. Nato se zdravilo SonoVue aplicira preko urinskega katetra.
SonoVue has no or negligible influence on the ability to drive and use machines.
Zdravilo SonoVue nima vpliva ali ima zanemarljivi vpliv na sposobnost vožnje in upravljanja s stroji.
In animal studies, the application of echo-contrast agents revealed biological adverse reactions (e.g. endothelial cell injury, capillary rupture) by interaction with the ultrasound beam.
Študije na živalih so pokazale, da je aplikacija eho-kontrastnega sredstva privedla do bioloških neželenih reakcij (npr. poškodba endotelijskih celic, ruptura kapilar) pri interakciji z ultrazvočnimi valovi.
The safety of SonoVue after intravesical administration was based on evaluation of published literature involving use of SonoVue in over 6000 paediatric patients (age range 2 days to 18 years).
Varnost zdravila SonoVue po intravezikalni uporabi temelji na oceni objavljene literature, ki vključuje uporabo zdravila SonoVue pri več kot 6000 pediatričnih bolnikih (starih od 2 dni do 18 let).
Once reconstituted, chemical and physical stability has been demonstrated for 6 hours.
Ko je kontrastno sredstvo pripravljeno, je njegova kemijska in fizikalna obstojnost 6 ur.
The total amount of sulphur hexafluoride administered in a clinical dose is extremely small, (in a 2 mL dose the microbubbles contain 16 µl of gas).
Celokupna količina žveplovega heksafluorida v kliničnem odmerku je izredno majhna (2 ml odmerek vsebuje 16 µl plina v obliki mikromehurčkov).
Clear, colourless solvent
Bister, brezbarven vehikel
This medicinal product contains less than 1 mmol sodium (23mg) per dose, i.e. essentially ‘sodiumfree'.
To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na odmerek, to v bistvu pomeni 'brez natrija'.
Tell your doctor straight away if you notice any of the following side effects, you may need medical treatment: swelling of the face, lips, mouth or throat which may make it difficult to swallow or breathe; skin rash; hives; swelling of the hands, feet or ankles.
Takoj obvestite zdravnika, če opazite katerega od naslednjih neželenih učinkov, saj boste morda potrebovali zdravljenje: - otekanje obraza, ustnic, ust ali žrela, kar lahko oteži požiranje ali dihanje, kožni izpuščaj,
Method of administration For instructions on reconstitution of the medicinal product before administration see section 6.6 .
Za navodila o rekonstrukciji zdravila pred uporabo glejte poglavje 6.6.
SonoVue dispersion should be administered within six hours of its preparation.
Disperzijo zdravila SonoVue je treba porabiti v roku šestih ur po pripravi.
SonoVue should only be used in patients where study without contrast enhancement is inconclusive.
Zdravilo SonoVue lahko uporabljamo samo pri bolnikih, kjer je preiskava brez kontrastnega sredstva neuspešna.
Keep this medicine out of the sight and reach of children Do not use this medicine after the expiry date which is stated on the label.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki.
If you have a serious pulmonary or cardiac condition you will be under close medical supervision during and for at least 30 minutes after the injection of SonoVue.
Če imate hudo pljučno ali srčno stanje, boste med injiciranjem zdravila SonoVue in vsaj 30 minut po njem pod strogim zdravniškim nadzorom.
Therefore, if SonoVue is to be used in conjunction with stress echocardiography patients must have a stable condition verified by absence of chest pain or ECG modification during the two preceding days.
Če se zdravilo SonoVue uporablja v povezavi z obremenitvenim testiranjem srca, morajo biti bolniki v preteklih dveh dneh v stabilnem stanju; s preverjeno odsotnostjo bolečine v prsnem košu ali brez EKG sprememb.
Myocardial infarction** Myocardial ischemia**
Srčne bolezni miokardni infarkt** miokardna ishemija**
Doppler of microvasculature
Doppler mikrovaskularizacije
Each millilitre of SonoVue contains 8 µL of the microbubbles.
En mililiter zdravila SonoVue vsebuje 8 µl mikromehurčkov.
METHOD AND ROUTE(S) OF ADMINISTRATION Intravenous or intravesical use Read the package leaflet before use.
POSTOPEK IN POT UPORABE ZDRAVILA Intravenska ali intravezikalna uporaba Pred uporabo preberite priloženo navodilo.
Use caution when treating anaphylaxis with epinephrine in patients on beta blockers since response may be poor or promote undesired alpha-adrenergic and vagotonic effects (hypertension, bradycardia).
Bodite previdni pri zdravljenju anafilaksije z adrenalinom pri bolnikih, ki jemljejo antagoniste adrenergičnih receptorjev beta, saj je odziv lahko slab ali pospeši alfa-adrenergične in vagotonične učinke (hipertenzija, bradikardija).
The filling and emptying of the bladder with saline solution may be repeated if needed.
Polnjenje in praznjenje mehurja s fiziološko raztopino, se lahko po potrebi ponovi.
* Cases suggestive of hypersensitivity may include: skin erythema, bradycardia, hypotension, dyspnoea, loss of consciousness, cardiac/cardio-respiratory arrest, anaphylactic reaction, anaphylactic shock.
* Primeri, ki kažejo na preobčutljivost, lahko vključujejo: kožni eritem, bradikardija, hipotenzija, težko dihanje, izguba zavesti, srčni/kardio-respiratorni zastoj, anafilaktične reakcije, anafilaktični šok.
In very rare cases, fatal outcomes have been reported in temporal association with the use of SonoVue.
V zelo redkih primerih so bili zabeleženi smrtni izidi ob dajanju zdravila SonoVue.
In a Phase I study doses up to 52 mL of SonoVue were administered to normal volunteers without serious adverse events being reported.
V fazi I kliničnega preskušanja so zdravi prostovoljci prejeli do 52 ml zdravila SonoVue in niso poročali o resnih neželenih učinkih.
PHARMACEUTICAL FORM AND CONTENTS 1 powder vial, 1 pre-filled syringe of solvent, 1 transfer system
FARMACEVTSKA OBLIKA IN VSEBNOST 1 viala s praškom, 1 napolnjena injekcijska brizga z vehiklom, sistem za prenos.
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2)
B. POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM Izdaja zdravila je le na recept s posebnim režimom (Glej Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
Ultrasound imaging of the bladder and kidneys is performed during filling and voiding of the bladder.
Ultrazvok mehurja in ledvic se izvaja med polnjenjem in praznjenjem mehurja.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu .
DATUM ZADNJE REVIZIJE BESEDILA Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila: http://www.ema.europa.eu.
Macrogol 4000, distearoylphosphatidylcholine, dipalmitoylphosphatidylglycerol sodium, palmitic acid, Solvent: sodium chloride 9 mg/mL
Makrogol 4000, distearilfosfatidilholin, natrijev fosfatidilglicerildipalmitat, palmitinska kislina Vehikel: 9 mg/ml raztopina natrijevega klorida
Rare (may affect up 1 in 1,000 people): - Blurred vision - Decrease in blood pressure - Itching - Back pain - Pain in general - Chest pain - Fatigue - Severe and less severe allergic reaction (including redness of the skin, decrease in heart rate,
Redki neželeni učinki (pojavijo se lahko pri največ 1 od 1.000 ljudi): - zamegljen vid, - znižanje krvnega tlaka, - srbenje, - bolečina v hrbtu, - splošna bolečina, - bolečina v prsnem košu, - utrujenost, - hude in manj hude alergijske reakcije (vključno s pordelo kožo, znižanjem srčnega utripa,
METHOD OF ADMINISTRATION Intravenous or intravesical use
POSTOPEK UPORABE Intravenska ali intravezikalna uporaba.
Talk to your doctor before you are given SonoVue if: - you had a recent myocardial infarction or a recent surgery on your coronary arteries, - you suffer from angina or chest pain or severe cardiac disease, - you suffer from severe heart rhythm disorders, - your cardiac disease has worsened recently, - you have an acute inflammation of the cardiac envelope (endocarditis), - you have artificial heart valves, - you have an acute general inflammation or infection, - you have known blood clotting problem, - you have severe kidney or liver diseases,
Preden prejmete zdravilo SonoVue, se pogovorite z zdravnikom, če: - ste imeli nedavno miokardni infarkt ali kirurški poseg na koronarnih arterijah, - imate angino ali bolečine v prsih ali hudo srčno bolezen, - trpite za hudimi motnjami srčnega ritma, - se je vaša srčna bolezen v zadnjem času poslabšala, - imate akutno vnetje srčne ovojnice (endokarditis), - imate umetne srčne zaklopke, - imate akutno sistemsko vnetje ali okužbo, - imate znano težavo s strjevanjem krvi, - imate hudo bolezen ledvic ali jeter,
The MAH shall complete, within the stated timeframe, the below measures:
Imetnik dovoljenja za promet bo izvedel sledeče ukrepe v predvidenem roku:
SonoVue is indicated for use in ultrasonography of the excretory tract in paediatric patients from newborn to 18 years to detect vesicoureteral reflux.
Zdravilo SonoVue je indicirano za uporabo pri ultrazvoku sečnih izvodil pri pediatričnih bolnikih od novorojenčka do 18. leta, za odkrivanje vezikoureternega refluksa.
What SonoVue is and what it is used for What you need to know before you are given SonoVue How SonoVue is given
Kaj je zdravilo SonoVue in za kaj ga uporabljamo Kaj morate vedeti, preden boste prejeli zdravilo SonoVue Kako uporabljati zdravilo SonoVue Možni neželeni učinki
SonoVue is an ultrasound contrast agent that contains tiny bubbles filled with a gas called sulphur hexafluoride.
Zdravilo SonoVue je kontrastno sredstvo za ultrazvočni pregled, ki vsebuje drobne mehurčke, napolnjene s plinom, imenovanim žveplov heksafluorid.
Use extreme caution when considering the administration of Sonvue in patients with recent acute coronary syndrome or clinically unstable ischaemic cardiac disease, including: evolving or ongoing myocardial infarction, typical angina at rest within last 7 days, significant worsening of cardiac symptoms within last 7 days, recent coronary artery intervention or other factors suggesting clinical instability (for example, recent deterioration of ECG, laboratory or clinical findings), acute cardiac failure, Class III/IV cardiac failure, or severe rhythm disorders because in these patients allergy like and/or vasodilatory reactions may lead to life threatening conditions.
Bodite izredno previdni, ko razmišljate o uporabi zdravila SonoVue pri bolnikih z nedavnim akutnim koronarnim sindromom ali klinično nestabilno ishemično boleznijo srca, vštevši razvijajoči se ali že obstoječi miokardni infarkt, tipično angino pektoris v mirovanju v zadnjih sedmih dneh, s pomembnim slabšanjem srčnih simptomov v zadnjih sedmih dneh, z nedavnim posegom na koronarnih arterijah ali z drugimi faktorji, ki bi kazali klinično nestabilnost (npr. nedavno poslabšanje EKG, laboratorijskih ali kliničnih izvidov), z akutno srčno odpovedjo, s srčno odpovedjo razreda III/IV ali hudo aritmijo, ker lahko pri teh bolnikih alergijam podobne in/ali vazodilatatorne reakcije vodijo v okoliščine, ki bi utegnile ogroziti življenje.
Paediatric population-Intravesical use
Pediatrična populacija - intravezikalna uporaba
The vial is for a single use only.
Viala je samo za enkratno uporabo.
If your are an adult SonoVue helps to obtain clearer ultrasound pictures of your heart, your blood vessels and/or tissues of the liver and breast.
Pri odraslih osebah zdravilo SonoVue pomaga pridobiti jasnejšo ultrazvočno sliko srca, ožilja in/ali tkiva jeter in prsi.
Uncommon side effects (may affect up to 1 in 100 people): - Headache - Numbness - Dizziness - Strange taste in the mouth - Redness - Chest discomfort - Feeling sick (nausea) - Abdominal pain - Skin rash - Feeling hot - Local reactions where the injection was given such as: pain or an unusual sensation at the injection site
občasni neželeni učinki(pojavijo se lahko pri največ 1 od 100 ljudi): - glavobol, - odrevenelost, - omotica, - čuden okus v ustih, - rdečina, - neprijeten občutek v prsnem košu, - siljenje na bruhanje (navzea), - bolečina v trebuhu, - kožni izpuščaj, - občutek vročine, - lokalne reakcije na mestu injiciranja, kot so: bolečina ali nenavaden občutek na mestu injiciranja.
SonoVue helps to obtain clearer pictures of the urinary tract in children .
Zdravilo SonoVue pomaga pridobiti jasnejšo sliko sečil pri otrocih.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of the dispersion contains 8 µL sulphur hexafluoride microbubbles, equivalent to 45 micrograms.
KAKOVOSTNA IN KOLIČINSKA SESTAVA En ml disperzije vsebuje 8 µl mikromehurčkov žveplovega heksafluorida, kar ustreza 45 mikrogramom.
Do not use SonoVue:
Ne uporabljajte zdravila SonoVue,
For patients under 18 years of age SonoVue can be used only for ultrasound of the urinary tract.
Pri bolnikih, mlajših od 18 let se zdravilo SonoVue lahko uporablja samo za ultrazvok sečil.
Intravenous use of SonoVue is contraindicated in patients known to have right-to-left shunts, severe pulmonary hypertension (pulmonary artery pressure >90 mmHg), uncontrolled systemic hypertension, and in patients with adult respiratory distress syndrome.
Intravenska uporaba zdravila SonoVue je kontraindicirana pri bolnikih z desno-levim šantom, akutnim endokarditisom, umetnimi srčnimi zaklopkami, s hudo pulmonalno hipertenzijo (pulmonalni arterijski tlak > 90 mm Hg), nenadzorovano hipertenzijo in pri odraslih bolnikih z respiratornim distresnim sindromom.
Invert the system and carefully withdraw SonoVue into the syringe.
Obrnite sistem in previdno potegnite SonoVue nazaj v injekcijsko brizgo.
In clinical trials, the most commonly reported adverse reactions after intravenous administration are: headache, injection site reaction, and nausea.
Najpogosteje poročani neželeni učinki po intravenski uporabi v kliničnih študijah so: glavobol, reakcija na mestu injiciranja, in navzea.
During a single examination, a second injection of the recommended dose can be made when deemed necessary by the physician.
Med preiskavo lahko zdravnik, kadar meni, da je potrebno, da še dodatni priporočeni odmerek.
Adverse Drug Reactions Frequency Category
Neželeni učinki zdravila Pogostost
However, based on its rapid elimination from the body via the expired air, it is considered that the breastfeeding can be resumed two to three hours after administration of SonoVue.
Ni znano, ali se žveplov heksafluorid izloča v materino mleko, vendar pa se, na podlagi hitrega izločanja iz telesa preko izdihanega zraka, smatra, da se lahko z dojenjem nadaljuje dve do tri ure po dajanju zdravila SonoVue.
SonoVue increases the quality of the Doppler flow image and the duration of clinically-useful signal enhancement in portal vein assessment in adult patients.
Zdravilo SonoVue poveča kakovost dopplerskega posnetka pretoka in trajanje klinično uporabnega pojačanega signala za preiskavo portalne vene pri odraslih bolnikih.
SonoVue is a kit which includes a glass vial containing white powder, a glass syringe containing the solvent and a transfer system.
Zdravilo SonoVue je pakiran v kompletu, ki vsebuje bel prašek, stekleno injekcijsko brizgo z vehiklom in sistem za prenos.
No adverse reactions were reported.
Neželeni učinki niso bili poročani.
For ultrasonography of the excretory urinary tract in paediatric patients, after intravesical administration, SonoVue increases the signal intensity of fluids within the urethra, bladder, ureters, and renal pelvis, and facilitates the detection of reflux of fluid from the bladder into the ureters.
Pri ultrazvoku sečnih izvodil pri otrocih, po intravezikalni uporabi, zdravilo SonoVue poveča jakost signala tekočin znotraj sečnice, mehurja, sečevodov in ledvičnega meha in tako omogoča odkrivanje refluksa tekočin iz mehurja v sečevode.
Nausea, Abdominal pain
Bolezni prebavil abdominalna bolečina, navzea bruhanje
What SonoVue looks like and contents of the pack
Izgled zdravila SonoVue in vsebina pakiranja
Immediately following the first voiding, the bladder may be refilled with saline for a second cycle of voiding and imaging, without the need of a second SonoVue administration.
Takoj po prvem praznjenju se lahko mehur napolni s fiziološko raztopino za drugi cikel praznjenja mehurja in slikanja, pri kateremu dodajanje zdravila SonoVue ni potrebno.
Type I colourless glass vial containing 25 mg of dry, lyophilised powder in an atmosphere of sulphur hexafluoride closed with a grey butyl rubber stopper and sealed with an aluminium crimp seal with a flip-off disc. A transfer system ( MiniSpike ).
Brezbarvna viala stekla tipa I vsebuje 25 mg suhega, liofiliziranega praška v atmosferi žveplovega heksafluorida, zaprta s sivim zamaškom iz butilne gume in zatesnjena z zoženim aluminijastim tesnilom z dvižno zaporko.
SonoVue increases the accuracy in detection or exclusion of abnormalities in cerebral arteries and extracranial carotid or peripheral arteries in adult patients by improving the Doppler signal to noise ratio.
Zdravilo SonoVue poveča natančnost pri zaznavanju ali izključitvi anomalij v cerebralnih arterijah in v ekstrakranialnih karotidnih arterijah ali perifernih arterijah pri odraslih bolnikih z izboljšanjem dopplerjevega razmerja med signalom in šumom.